Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 1, 2010, Pages 143-146

  Shokry, Mahmoud ^a,e   Bedaiwy, Mohamed A ^a,b   Fathalla, Mohamed M F ^a   Alsemary, Ali ^c   Elwakil, Sahar ^d   Murphy, Aisling ^b  

^a ASSIUT UNIVERSITY   (Egypt)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CAIRO UNIVERSITY   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

^e Saudi German Hospital   (Saudi Arabia)

Author keywords

Angiogenic factors; Placental growth factor; Preeclampsia; Soluble fms like tyrosine kinase 1

Indexed keywords

FLT1 PROTEIN, HUMAN; GROWTH HORMONE; HGH V PROTEIN, HUMAN; HGH-V PROTEIN, HUMAN; PLACENTAL PEPTIDE HORMONE; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; METABOLISM; NEUTROPHIL; PHYSIOLOGY; PREDICTION AND FORECASTING; PREECLAMPSIA; PREGNANCY; SECOND TRIMESTER PREGNANCY; SOLUBILITY;

ADULT; FEMALE; GROWTH HORMONE; HUMANS; NEUTROPHILS; PLACENTAL HORMONES; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 74049164699     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903289892     Document Type: Article

References (11)

1. Polliotti BM, Fry AG, Saller D.N., Mooney RA, Cox C, Miller RK Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003; 101: 1266-74.
2. Thadhani R, Mutter WP, Wolf M, Levine R.J., Taylor RN, Sukhatme VP, et al First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004; 89:770-5.
3. Krysiak O, Bretschneider A, Zhong E., Webb J, Hopp H, Verlohren S., et al Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with pre-eclampsia from additional migration by VEGF. Circ Res. 2005; 97:1253-61.
4. Maynard SE, Min JY, Merchan J, Lim K.H., Li J., Mondal S, et al Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111:649-58.
5. Taylor RN, Grimwood J, Taylor R.S., McMaster MT, Fisher SJ, North RA Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003; 188:177-82.
6. Cohen A, Lim KH, Lee Y, Rana S., Karumanchi SA, Brown F. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007; 30:375-7.
7. Levine RJ, Maynard SE, Qian C, Lim K.H., England LJ, Yu KF, et al Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350:672-83.
8. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest. 2003; 111:600-2.
9. Livingston JC, Haddad B, Gorski L.A., Neblett P., Ahokas RA, Ramsey R, et al Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol. 2001; 184:1218-20.
10. Ong CY, Liao AW, Cacho A.M., Spencer K., Nicolaides KH First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Obstet Gynecol. 2001; 98:608-11.
11. Powers RW, Roberts JM, Cooper K.M., Gallaher MJ, Frank MP, Harger GF, et al Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol. 2005; 193:185-91.